Inhaled molgramostim + Antimycobacterial regimen
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mycobacterium Infections, Nontuberculous
Conditions
Mycobacterium Infections, Nontuberculous
Trial Timeline
Mar 1, 2018 → Jan 13, 2020
NCT ID
NCT03421743About Inhaled molgramostim + Antimycobacterial regimen
Inhaled molgramostim + Antimycobacterial regimen is a phase 2 stage product being developed by Savara for Mycobacterium Infections, Nontuberculous. The current trial status is completed. This product is registered under clinical trial identifier NCT03421743. Target conditions include Mycobacterium Infections, Nontuberculous.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03421743 | Phase 2 | Completed |
Competing Products
20 competing products in Mycobacterium Infections, Nontuberculous